NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will
present important research findings together with researchers at Lund University
in three scientific poster presentations at the conference entitled
“Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease”
being held 4-6 May 2016 in Cambridge, United Kingdom.
The three scientific contributions submitted by the NeuroVive and Lund
University research team have been accepted for poster presentation at the
upcoming mitochondrial conference where global mitochondrial experts will be
gathered. The posters focus on different aspects of mitochondrial disorders
research and two of them are directly related to NeuroVive’s discovery platform
NVP015 which has the overall goal to generate novel drug candidates that target
mitochondrial energy regulation in a number of orphan diseases associated with
complex I deficiency.

The research that will be presented next week focuses on the role of NeuroVive’s
succinate prodrug candidates in mitochondrial respiration, potential value of
platelet respirometry in diagnosing mitochondrial disease and the role of
mitochondrial energy substrates as a new treatment strategy in patients with
MALA (Metformin-Associated Lactic Acidosis). Further, it is also demonstrated
that the prodrug strategy used for succinate also can be applied to other
selected mitochondrial substrates/intermediates. The research was conducted by
NeuroVive’s scientific research team, including Sarah Piel and Johannes K.
Ehinger and academic researchers from Lund University.

“We are very pleased that our team will present findings from different areas of
our research as this demonstrates the breadth of our mitochondrial research
expertise. We have been making good progress and to be able to share and discuss
our findings with other mitochondrial disease experts and key opinion leaders is
a fantastic opportunity. This interaction is important as we continue to develop
our exiting projects towards becoming medicines in orphan disease areas where
alternative treatments are very much needed. ” said Dr. Eskil Elmér, Chief
Scientific Officer at NeuroVive.

About NeuroVive’s Complex I Deficiency discovery program
This discovery platform is based on an idea by NeuroVive co-founder Dr. Eskil
Elmér and collaborators to create a cell permeable pro-drug of the endogenous
energy substrate succinate. Successful delivery will make succinate available to
complex II in the respiratory chain supporting production of energy-carrying ATP
molecules in spite of complex I disorders. A successful candidate from this
discovery program in paediatric mitochondrial disorders would classify as an
orphan drug.

For further information regarding NeuroVive’s first and second generation of
succinate prodrugs, see the following published patent applications:

  · Protected succinates for enhancing mitochondrial ATP
-production https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014053857
  · Prodrugs of succinic acid for increasing ATP
production https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015155230
  · Novel cell-permeable succinate
compounds https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015155231
  · Succinate prodrugs for use in the treatment of lactic acidosis or drug
-induced side-effects due to complex I-related impairment of mitochondrial
oxidative
phosphorylation https://patentscope.wipo.int/search/en/detail.jsf?docId=WO201515
5 
238

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in
clinical and preclinical development and two drug discovery platforms. The
NeuroSTAT® product has orphan drug status in Europe and in the US for treatment
of moderate to severe traumatic brain injury and is currently being evaluated in
a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares
are listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on the 28 April 2016, at 08.45 CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ Stockholm, Small Cap, under the ticker symbol NVP.
The share is also traded on the OTC market in the US. NeuroVive Pharmaceutical
(OTC: NEVPF) trades on the OTC Pink Market. Investors can find Real-Time quotes
and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)